Guest
Guest
Apr 17, 2026
1:59 AM
|
The first immune checkpoint inhibitor, which targeted CTLA-4, was approved by the FDA in 2011, providing proof of concept that checkpoint inhibitors can be used to modulate the immune system to attack cancer cells. Then, many biotechnology companies began to search for other targets and develop molecules to target them. Typical examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/CD80/CD86.
|